IPG Photonics Reports $288 Million Quarterly Sales
The laser maker's September quarter results rose 15 percent year-on-year as it awaits the closing of its Lumibird Medical acquisition.
Updated on Nov. 4, 2026 in Quantum Computing
IPG Photonics reported sales revenues of $288 million for the September 2026 quarter, up 15 percent year-on-year, with pre-tax income of $28.4 million, nearly double the prior year. The company said a significant number of Crossbow laser weapons were shipped to Lockheed Martin during the quarter.
Why it matters
The results show growth in the company's defense and industrial laser business at a time when its stock has fallen more than half from a February high of just over $150. Expected fourth-quarter sales of $265 million to $295 million and an anticipated close of the Lumibird Medical deal will shape the company's trajectory into 2027.
IPG Photonics recorded $288 million in September quarter sales and $28.4 million in pre-tax income, against 2025 annual sales of just over $1 billion. The filing does not explain the technical performance or pricing of the Crossbow systems shipped to Lockheed Martin.
The players
IPG Photonics
A fiber laser manufacturer whose products are used in industrial, medical and defense applications.
Lockheed Martin
A major U.S. defense contractor and the lead customer for IPG Photonics' Crossbow laser weapons.
Lumibird Medical
A medical technology company based in France whose planned acquisition by IPG Photonics is expected to close shortly.
The details
IPG Photonics shipped a significant number of Crossbow laser weapons to lead customer Lockheed Martin during the quarter. The company also secured new additive manufacturing business in Europe. Its stock price has held near $74 after losing more than half its value since February.
Timeline
February 2026: IPG Photonics stock reaches a short-term high above $150.
September 2026 quarter: Company reports $288 million in sales and $28.4 million pre-tax income.
End of 2026: Remaining Crossbow shipments to Lockheed Martin are scheduled for completion.
Fourth quarter 2026: Company expects sales of $265 million to $295 million.
Shortly: Lumibird Medical acquisition expected to close.
The Tech Race
The Crossbow shipments to Lockheed Martin mark a move of IPG Photonics' high-power fiber laser technology into defense delivery volumes. The company's medical expansion through Lumibird Medical positions it against other laser suppliers serving both sectors.
Investors holding IPG Photonics shares face a stock that has fallen to around $74 from a February high above $150. Customers and suppliers in industrial and medical laser markets may see the effects of the company's expanded medical portfolio once the Lumibird Medical deal closes.
The takeaway
IPG Photonics' quarter shows the company growing its defense and industrial laser business even as its share price has fallen sharply. Readers following laser and photonics suppliers should watch the Lumibird Medical closing and fourth-quarter results to judge whether the growth holds.
What happens next
IPG Photonics expects its Lumibird Medical acquisition to close shortly and anticipates fourth-quarter 2026 sales between $265 million and $295 million.
Further reading
For related coverage, see Quantum Computing in our tech section.
Source note: This article includes information reported by Optics.
